How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,721 results for

Antibiotic Food Interactions

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

122. Prevention and Control of Methecillin-Resistant Staphylcoccus Aureus (MRSA)

will use clinical judgment and knowledge in applying the general principles and recommendations contained in this document. Recommendations may not be appropriate in all circumstances and decisions to adopt specific recommendations should be made by the practitioner taking into account the circumstances presented by individual patients and available resources. Antibiotic stewardship is the subject of on-going research and debate. Local antibiotic susceptibility data should be used to guide treatment (...) : Elements of a programme to prevent and control MRSA to promote safe quality care 7 Table 2: Key Components of Standard Precautions 22 Table 3: Practical guidance on antibiotic choices for the management of moderate CA-MRSA SSTI 33 Table 4: Definition of contacts of CA-MRSA index cases 36 Table 5: Risk Factors for MRSA in HCWs 50 Table 6: Treatment - practical guidance for MRSA infections in adults 57 Table 7: Estimation of the costs of HCAI in Ireland for 2011 extrapolated from national

2019 National Clinical Guidelines (Ireland)

123. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

2019 ii Key Messages Purpose of Review To evaluate the effectiveness and harms of pharmacologic and nonpharmacologic treatments for exacerbations of chronic obstructive pulmonary disease. Key Messages • Antibiotic therapy increases the clinical cure rate and reduces the clinical failure rate. • Oral and intravenous corticosteroids improve dyspnea and reduce the clinical failure rate. • Antibiotics and corticosteroids are not associated with increase in serious adverse events. • The evidence (...) is insufficient to support the effect of aminophyllines, magnesium sulfate, mucolytics, inhaled corticosteroids, inhaled antibiotics, 5-lipoxygenase inhibitor, and statins on mortality, dyspnea, need for intubation, clinical failure, or hospital admission. • Titrated oxygen reduces mortality compared with high flow oxygen. • The evidence suggests benefits of some nonpharmacologic interventions such as chest physiotherapy using vibration/percussion/massage or using breathing technique (on dyspnea), resistance

2019 Effective Health Care Program (AHRQ)

124. Integrated care for older people (?ICOPE)?: guidance for person-centred assessment and pathways in primary care

-related attributes that enable people to be and to do what they have reason to value”. Functional ability consists of the intrinsic capacity of the individual, the environment of the individual and the interactions between them. Intrinsic capacity is “the composite of all the physical and mental capacities that an individual can draw on” (1). This concept of healthy ageing inspires a new focus for health care in older age a focus on optimiing people’s intrinsic capacity and functional ability (...) of the individual’s physical and mental, including psychological, capacities. Functional ability is the combination and interaction of intrinsic capacity with the environment a person inhabits. 62 How to carry out a person-centred, integrated approach at the primary health-care level FIGURE 2. A PUBLIC-HEALTH FRAMEWORK FOR HEALTHY AGEING: OPPORTUNITIES FOR PUBLIC HEALTH ACTION ACROSS THE LIFE COURSE High and stable capacity HEALTH SERVICES: LONG-TERM CARE: ENVIRONMENTS: Declining capacity igni?cant loss

2019 World Health Organisation Guidelines

125. Surveillance, Diagnosis and Management of Clostridium Difficile Infection in Ireland

campaigns have been linked to the annual European Antibiotic Awareness Day (www.hse.ie/ go/antibiotics). In the UK, there have been several efforts to increase public awareness of the 31 A National Clinical Guideline Clostridium difficile Infection in Ireland appropriate use of antimicrobials.(66) The first campaign ‘Andybiotic’ began in 1999 and was repeated in 2000, 2002, 2003 and 2006. The impact of the campaign was assessed before and after it was run. There was a small increase in the overall

2019 National Clinical Guidelines (Ireland)

126. Stroke, Diagnosis and Initial Treatment of Ischemic Stroke

, 2016) . Of all strokes, 87% are ischemic strokes (Mozaffarian, 2015). In Minnesota, ischemic stroke death rate – regardless of gender and age group – is at 19 per 100,000, compared to the national rate of 20 per 100,000, for years 2011- 2013 per the Centers for Disease Control and Prevention's Interactive Atlas of Heart Disease and Stroke. In the United States, one person dies from stroke every four minutes, on average (Mozaffarian, 2015). Therefore, time is of the essence in getting appropriate (...) thrombolytic treatment.” 1.6 Telemedicine 1. For sites without in-house imaging interpretation expertise, teleradiology systems approved by the US Food and Drug Administration are recommended for timely review of brain imaging in patients with suspected acute stroke. (COR I; LOE A) (Recommendation revised from 2013 AIS Guidelines.) Agree Return to Table of Contents Institute for Clinical Systems Improvement www.icsi.org 9 Diagnosis and Initial Treatment of Ischemic Stroke Recommendations Twelfth Edition

2019 Institute for Clinical Systems Improvement

127. Management of Infants at Risk for Group B Streptococcal Disease

of Infants at Risk for Group B Streptococcal Disease Karen M. Puopolo , Ruth Lynfield , James J. Cummings , COMMITTEE ON FETUS AND NEWBORN , COMMITTEE ON INFECTIOUS DISEASES This article has a correction. Please see: Abstract Group B streptococcal (GBS) infection remains the most common cause of neonatal early-onset sepsis and a significant cause of late-onset sepsis among young infants. Administration of intrapartum antibiotic prophylaxis is the only currently available effective strategy (...) for the prevention of perinatal GBS early-onset disease, and there is no effective approach for the prevention of late-onset disease. The American Academy of Pediatrics joins with the American College of Obstetricians and Gynecologists to reaffirm the use of universal antenatal microbiologic-based testing for the detection of maternal GBS colonization to facilitate appropriate administration of intrapartum antibiotic prophylaxis. The purpose of this clinical report is to provide neonatal clinicians with updated

2019 American Academy of Pediatrics

128. Screening and Management of the Hyperandrogenic Adolescent

and can be increased to a maximum dosage of 100–200 mg/d (19). Oral antibiotics are typically used for moderate-to- severe acne, acne on the chest and back, and with inflammatory lesions where topical agents have not been useful.Itisrecommendedthatoralantibioticsbetaperedor discontinued once new inflammatory lesions have stopped emerging, and other therapies may be used for mainte- nance (8, 27). Current antibiotics recommended for acne do not interact with hormonal contraception (29). Patients (...) not as first line therapy? Facts and controversies. Clin Dermatol 2010;28:17–23. 29. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hor- monal contraception: a systematic review. Am J Obstet Gynecol 2018;218:88–97.e14. VOL. 134, NO. 4, OCTOBER 2019 Committee Opinion Hyperandrogenic Adolescent e113Published online on September 24, 2019. Copyright 2019 by the American College of Obstetricians and Gynecologists. All rights reserved. No part

2019 American College of Obstetricians and Gynecologists

129. BTS/SIGN British Guideline on the Management of Asthma

This guideline will be of particular interest to healthcare professionals involved in the care of people with asthma including general practitioners, consultants and specialists in respiratory medicine, nurses, pharmacists and other allied health professionals with an interest in respiratory care. The guideline will also be of interest to people with asthma, their parents and carers; those who interact with people with asthma outside of the NHS, such as teachers; voluntary organisations with an interest (...) 25 Table 5: Clinical clues to alternative diagnoses in adults Clinical clue Possible diagnosis Without airflow obstruction Predominant cough without lung function abnormalities Chronic cough syndromes; pertussis Prominent dizziness, light-headedness, peripheral tingling Dysfunctional breathing Recurrent severe ‘asthma attacks’ without objective confirmatory evidence Vocal cord dysfunction Predominant nasal symptoms without lung function abnormalities Rhinitis Postural and food-related symptoms

2019 British Thoracic Society

130. Plitidepsin (Aplidin) - Multiple Myeloma

Electrocardiogram ECOG Eastern Cooperative Oncology Group eEF1A2 EFS Eukaryotic Elongation Factor 1A2 Event free survival EMA ER ERK European Medicines Agency Endoplasmic Reticulum extracellular signal–regulated kinases ESMO European Society of Medical Oncology EU European Union F Female FDA Food and Drug Administration (USA) GC Gas chromatography GCP GFR GLP Good Clinical Practice Glomerular filtration rate Good Laboratory Practice HDAC Histone Deacetylase Inhibitor HDPE High density polyethylene HPLC High (...) , Aplidium albicans. Plitidepsin interacts with eEF1A2, a protein described to have oncogenic properties. The compound triggers the generation of early oxidative stress, which induces the sustained activation of MAPK signalling cascades that finally lead to apoptosis. The applicant applied for the following indication: Aplidin is indicated in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (MM) who have received at least three prior regimens

2018 European Medicines Agency - EPARs

131. Caplacizumab (Cablivi) - thrombotic thrombocytopenic purpura (aTTP)

-caplacizumab nanobody. Bioanalysis of pharmacodynamic markers and ADA The activity of the drug is also monitored using the Ristocetin Induced Platelet Aggregation (RIPA) or Ristocetin Cofactor Activity (RICO) Assay as a pharmacodynamics (PD) marker. The antibiotic Ristocetin activates vWF, which is similar to high shear blood flow conditions which causes platelet agglutination. The mechanism can be blocked by the interaction of caplacizumab with vWF. Both assays yield equivalent results but an advantage (...) , Terrell et al., 2005, Reese et al., 2013, Kremer Hovinga et al., 2017). In the EU, the annual incidence of aTTP has been reported to be between 1.5 and 6 cases per million per year (Miller et al., 2004, Scully et al., 2008, Hassan et al., 2015, Veyradier et al., 2015). The incidence in children ( 20-fold to the predicted clinical exposure for the recommended dose of caplacizumab (10 mg/day, AUC=300 µg h/mL) as shown below: Pharmacodynamic drug interactions No dedicated pharmacodynamic drug interaction

2018 European Medicines Agency - EPARs

132. Tezacaftor / ivacaftor (Symkevi) - cystic fibrosis

of the tubes from the pancreas slows down the digestion of food and causes poor growth. Symkevi is used in patients who have a mutation (change) called F508del in the gene for a protein called ‘cystic fibrosis transmembrane conductance regulator’ (CFTR). Symkevi is used in patients who have inherited the F508del mutation from both parents and therefore have the mutation in both copies of the CFTR gene. It is also used in patients who have inherited the F508del mutation from one parent and also have one (...) (tezacaftor / ivacaftor) EMA/CHMP/774318/2018 Page 2/3 The doses of Symkevi and ivacaftor may need to be adjusted if the patient is also taking a type of medicine called a ‘moderate or strong CYP3A inhibitor’, such as certain antibiotics or medicines for fungal infections. The doses may also need to be adjusted in patients with reduced liver function. For more information about using Symkevi, see the package leaflet or contact your doctor or pharmacist. How does Symkevi work? Cystic fibrosis is caused

2018 European Medicines Agency - EPARs

133. Vestronidase alfa (Mepsevii) - Mucopolysaccharidosis VII

EU European Union FDA Food and Drug Administration FVC Forced vital capacity GAG Glycosaminoglycan GCP Good Clinical Practice GEE Generalized Estimating Equation GLP Good Laboratory Practice GMP Good Manufacturing Practice GUS Beta-glucuronidase HS Heparan sulfate HSCT Haematopoietic stem cell transplantation IAR Infusion associated reaction Assessment report EMA/480950/2018 Page 5/87 ICH International Conference on Harmonisation ICR Individualized clinical response IND Investigational New Drug

2018 European Medicines Agency - EPARs

134. Gemtuzumab ozogamicin (Mylotarg) - Leukemia, Myeloid, Acute

Cooperative Oncology Group ED50, ED90, ED95 dose that produces 50%/90%/95% of maximum response EFS event-free survival ELISA enzyme-linked immunosorbent assay ELN European Leukemia Network EMA European Medicines Agency Emax maximum achievable response EOP end of production Assessment report EMA/155284/2018 Page 5/138 EU European Union EU Endotoxin Units FDA Food and Drug Administration FLAG-Ida fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin FLT3 FMS-like tyrosine kinase 3 (...) with the batch. The gemtuzumab ozogamicin active substance is filled in sterile bags, compliant with European Pharmacopoeia (Ph. Eur.) and food contact legislation (EC Regulation No 1183/2012 replacing No 10/2011). Extractable and leachables evaluation is satisfactory. The active substance is stored at appropriate storage conditions. Control of materials Sufficient information on raw materials used in the active substance manufacturing process has been submitted. Compendial raw materials are tested

2018 European Medicines Agency - EPARs

135. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Spectrometry ET Early termination EU European Union EULAR European League Against Rheumatism Fab domain Fragment antigen binding domain FDA Food and Drug Administration FU Follow-up GCP Good Clinical Practice G0F N-linked glycan with zero terminal galactose residue G1F N-linked glycan with one terminal galactose residue HAQ-DI Health Assessment Questionnaire -Disability Index HBV Hepatitis B virus H chain / HC Heavy chain HILIC Hydrophilic Interaction Liquid Chromatography iCE Imaged Capillary (...) Electrophoresis ICH International Conference on Harmonisation ID Identification IgG1 Immunoglobulin G 1 IP Investigational product IRR Infusion-related reaction CHMP assessment report EMA/223369/2018 Page 5/106 ITT Intent-to-Treat IV Intravenously administered IWRS Interactive web-based response system LC Liquid Chromatography L chain / LC Light chain LD Last dose LLOQ Lower limit of quantification mAB Monoclonal Antibody MS Mass Spectrometry NAb Neutralizing antibody NC Not calculated NCI National Cancer

2018 European Medicines Agency - EPARs

136. Reducing Acute Care Length of Stay in Newfoundland & Labrador

common (see Table 8) with variable implementation. Table 8: Elements of colorectal surgery Care Pathways, based on included evidence NLCAHR October 2017 | Reducing Acute Care Length of Stay in Newfoundland & Labrador 23 Elements that are more common and have a more standardized implementation method are assumed to play a more critical role in the effectiveness of the Care Pathway. The most common preoperative elements shared by the majority of studies were: ? Counselling (76%), ? Restriction of foods

2018 Newfoundland and Labrador Centre for Health Information

137. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. (PubMed)

participant data were excluded from the analysis. The trial was assessed as high risk of bias for selective outcome reporting, especially when reporting on the trial's post hoc subgroup of participants by chronic inhaled antibiotic use.The trial was sponsored by PTC Therapeutics Incorporated with grant support by the Cystic Fibrosis Foundation, the Food and Drug Administration's Office of Orphan Products Development and the National Institutes of Health (NIH).The trial reported no significant difference (...) a reduced rate of pulmonary exacerbation compared to those not receiving chronic inhaled tobramycin. This drug interaction was not anticipated and may affect the interpretation of the trial results.There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with cystic fibrosis with class I mutations. Future trials should carefully assess for adverse events, notably renal impairment and consider the possibility of drug interactions. Cross-over trials should

Full Text available with Trip Pro

2017 Cochrane

138. Appropriate care at the end of life

indications, e.g., Braga 1 refers to studies in which percentages of oncology patients that receive chemotherapy in the last month of their life vary between 8 and 50%; Albrecht et al. 2 found that 27% of hospice patients received an antibiotic during the last seven days of life, most without a documented infectious diagnosis; a Dutch study 3 found that 62% of physicians agreed that patients at the end of life are longer treated than desirable. In Belgium, Gielen et al. 4 found that 51% of patients (...) their reflections on a time and place that is best suited for them – no one needs to travel. In addition, since respondents write down their reflections on the forum, researchers do not need to spend time to transcribe the input provided. On the other hand, no real interactions take place, making it sometimes difficult to interpret the written quotes in a nuanced way. Yet, because of the practicalities, we decided to copy this procedure, but choose to organise separate online focus groups for relatives (n=2; 1

2018 Belgian Health Care Knowledge Centre

139. Asthma

update. Ciclesonide (Alvesco ® ) is no longer a black triangle product. Minor addition to text regarding drug interactions with theophylline. Issued in January 2010. December 2009 — minor update. Clenil Modulite ® (beclometasone CFC-free) is no longer a black triangle product. Prescription updated. Issued in December 2009. November 2009 — minor update. The Supporting evidence section on Symbicort Smart® has been reworded to make it clear that the data summarized are from a single Cochrane review (...) asthma in an adolescent. British Medical Journal. [ ] Stefan, M., Shieh, M-S., and Spitzer, K. (2019) Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids. JAMA Internal Medicine. [ ] Primary evidence NEJM (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine. [ ] Biospace Inc. (2018) GSK announces long-term data on mepolizumab in patients with severe

2017 Prodigy

140. Antiocoagulation - oral

to include recommendations and supporting evidence on the place of self-testing and self-management of warfarin. Advice on the management of the drug interaction between selective serotonin reuptake inhibitors (SSRIs) and warfarin has also been added. July 2009 — updated to include target INRs and duration of treatment for all indications for warfarin. A change to the recommendation concerning management of potential drug interaction between warfarin and macrolide antibiotics has also been made. December (...) of interaction with vitamin K antagonists and changes in INR. October to November 2016 — reviewed. A literature search was conducted in October 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Information about edoxaban, a new anticoagulant has been added to this topic. Previous changes October 2015 — minor update. Based on an update to the manufacturer's Summary of Product Characteristics (SPC

2017 Prodigy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>